T 0872/13 (Factor VII Glycoforms/NOVO NORDISK) vom 28.08.2018
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2018:T087213.20180828
- Datum der Entscheidung
- 28. August 2018
- Aktenzeichen
- T 0872/13
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 05766825.3
- IPC-Klasse
- C07K 14/745C12P 21/00C12N 9/64
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- O-LINKED GLYCOFORMS OF FACTOR VII AND METHOD TO MANUFACTURE THEM
- Name des Antragstellers
- Novo Nordisk Health Care AG
- Name des Einsprechenden
- Strawman Limited
- Kammer
- 3.3.01
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 100(a)European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54(2)European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 84European Patent Convention R 115(2)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13Rules of procedure of the Boards of Appeal Art 15(3)
- Schlagwörter
- Oral proceedings - held in absence of appellant
Acceleration of proceedings - (no)
Late-filed evidence - submitted with the statement of grounds of appeal or reply thereto: admitted
Late-filed evidence - submitted at a late stage of appeal proceedings and complex: not admitted
Novelty - implicit disclosure (yes/no)
Amendments - allowable (yes)
Claims - clarity after amendment (yes)
Sufficiency of disclosure - (yes)
Inventive step - (yes) - Orientierungssatz
- -
- Zitierende Akten
- T 1114/22
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the
order to maintain the patent as amended in the following
version:
- claims 1 to 6 filed as auxiliary request 3 with the letter dated 9 September 2013,
- description: pages 2, 2a, 3 to 13 filed at the oral proceedings of 28 August 2018 and pages 14 to 20 of the patent specification, and
- drawings: figures 1 to 8b of the patent specification.